← Back to Search

Curcumin

Theracurmin HP for Amyotrophic Lateral Sclerosis

Phase 2
Waitlist Available
Led By Richard Bedlack, MD, PhD
Research Sponsored by Richard Bedlack, M.D., Ph.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 1, month 6
Awards & highlights

Study Summary

This study is evaluating whether a virtual reality program may help individuals with autism spectrum disorder.

Eligible Conditions
  • Amyotrophic Lateral Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 1, month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 1, month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in ALSFRS-R Slope
Secondary outcome measures
Enrollment Rate
Faith's Phylogenetic Diversity of the Oral Microbiome
Faith's Phylogenetic Diversity of the Stool Microbiome
+9 more

Side effects data

From 2022 Phase 2 trial • 100 Patients • NCT04499963
22%
Diarrhea, loose stools
6%
COVID Infection
6%
Hot flashes
4%
Itching
4%
Increased weakness
2%
Flu-like symptoms
2%
Cramps
2%
Headache
2%
Constipation
2%
Abdominal pain
2%
Pulmonary embolus
2%
Rash
2%
Anxiety
2%
Malaise
100%
80%
60%
40%
20%
0%
Study treatment Arm
Open Label Arm
Healthy Control Arm

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Open Label ArmExperimental Treatment1 Intervention
The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
Group II: Healthy Control ArmActive Control1 Intervention
We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Theracurmin HP
2020
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Richard Bedlack, M.D., Ph.D.Lead Sponsor
2 Previous Clinical Trials
75 Total Patients Enrolled
2 Trials studying Amyotrophic Lateral Sclerosis
75 Patients Enrolled for Amyotrophic Lateral Sclerosis
Richard Bedlack, MD, PhDPrincipal InvestigatorDuke University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
Richard Bedlack, M.D., Ph.D. 2020. "Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04499963.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top